BRPI0318114B8 - Vacinação ou imunização utilizando um regime de iniciação-reforço - Google Patents

Vacinação ou imunização utilizando um regime de iniciação-reforço

Info

Publication number
BRPI0318114B8
BRPI0318114B8 BRPI0318114A BRPI0318114A BRPI0318114B8 BR PI0318114 B8 BRPI0318114 B8 BR PI0318114B8 BR PI0318114 A BRPI0318114 A BR PI0318114A BR PI0318114 A BRPI0318114 A BR PI0318114A BR PI0318114 B8 BRPI0318114 B8 BR PI0318114B8
Authority
BR
Brazil
Prior art keywords
vaccination
immunization
initiation
booster regimen
regimen
Prior art date
Application number
BRPI0318114A
Other languages
English (en)
Inventor
Barzu-Le-Roux Simona
Francis Audonnet Jean-Christophe
Bernard Fischer Laurent
Original Assignee
Merial Ltd
Merial Inc
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Merial Inc, Boehringer Ingelheim Animal Health Usa Inc filed Critical Merial Ltd
Publication of BRPI0318114B8 publication Critical patent/BRPI0318114B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"VACINAÇÃO OU IMUNIZAÇÃO UTILIZANDO UM REGIME DE INICIAÇÃO-REFORÇO". A presente invenção refere-se a processos e composições e kits para a vacinação ou a imunização de um animal, tal como um mamífero, vantajosamente um bovino, que envolve um regime de iniciação-reforço.
BRPI0318114A 2003-02-19 2003-02-19 Vacinação ou imunização utilizando um regime de iniciação-reforço BRPI0318114B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/001215 WO2004073737A1 (en) 2003-02-19 2003-02-19 Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3

Publications (1)

Publication Number Publication Date
BRPI0318114B8 true BRPI0318114B8 (pt) 2022-07-05

Family

ID=32894013

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0318114-6A BR0318114B1 (pt) 2003-02-19 2003-02-19 Vacinação ou imunização utilizando um regime de iniciação-reforço
BRPI0318114A BRPI0318114B8 (pt) 2003-02-19 2003-02-19 Vacinação ou imunização utilizando um regime de iniciação-reforço

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0318114-6A BR0318114B1 (pt) 2003-02-19 2003-02-19 Vacinação ou imunização utilizando um regime de iniciação-reforço

Country Status (7)

Country Link
EP (1) EP1594537B1 (pt)
AU (1) AU2003215835B2 (pt)
BR (2) BR0318114B1 (pt)
CA (1) CA2515978A1 (pt)
MX (1) MXPA05008756A (pt)
NZ (1) NZ541879A (pt)
WO (1) WO2004073737A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
CN107779457B (zh) * 2016-08-29 2021-07-23 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131851A (en) 1965-02-10 1968-10-30 English Electric Co Ltd Electrical protective devices
EP0260148A3 (en) 1986-09-12 1989-06-07 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
AU9128391A (en) * 1990-11-05 1992-05-26 Siba Kumar Samal Bovine respiratory syncytial virus genes
NL9100989A (nl) 1991-06-07 1993-01-04 Stichting Centr Diergeneeskund Bovine herpesvirus type 1 deletiemutanten, daarop gebaseerde vaccins, diagnostische kits voor detectie van bovine herpesvirus type 1.
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19633684A1 (de) 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
JP4812914B2 (ja) 1997-06-23 2011-11-09 ユニバーシティ オブ サスカチュワン ウシアデノウイルスタイプ3ゲノム
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente

Also Published As

Publication number Publication date
AU2003215835A1 (en) 2004-09-09
EP1594537A1 (en) 2005-11-16
AU2003215835B2 (en) 2009-12-10
WO2004073737A1 (en) 2004-09-02
BR0318114A (pt) 2006-02-07
MXPA05008756A (es) 2005-10-05
BR0318114B1 (pt) 2014-09-02
CA2515978A1 (en) 2004-09-02
NZ541879A (en) 2009-02-28
EP1594537B1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
BRPI0715396B8 (pt) método de produção de uma composição para vacina
CO6331297A2 (es) Composiciones adyuvantes novedosas
CR11017A (es) Anticuerpos anti-robo4 y sus usos
BRPI0506726B8 (pt) anticorpo monoclonal específico para m-csf e usos deste
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
PA8672101A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
CR7742A (es) Formulaciones para uso veterinario que contienen productos de origen no animal
AR111157A2 (es) Secuencia reguladora de plantas
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
ATE426412T1 (de) Adjuvante influenza-vakzine
CR9606A (es) Anticuerpos anti-proteina quinoatrayente de monocitos-1, composiciones, metodos y usos
BRPI0807828B8 (pt) composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos
ATE438638T1 (de) Sulfoniumsalze als photoinitiatoren für strahlungshärtbare systeme
AR066395A1 (es) Reovirus que tienen secuencias modificadas
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
DK1978823T3 (da) Sammensætninger og fremgangsmåde til at fremme fedttab
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/09/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2278 DE02/09/2014, QUANTO AO NOME DO PROCURADOR.

B25C Requirement related to requested transfer of rights
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved